2019 American Transplant Congress
Donor Graft CMV Serostatus Influences the Development of Arterial and Venous Vascular Events in Seronegative Recipients after Organ Transplantation
University of Alberta, Edmonton, AB, Canada
*Purpose: Cytomegalovirus (CMV) is the most common opportunistic pathogen following solid organ transplantation (SOT) and is a major cause of morbidity and mortality. CMV infection…2019 American Transplant Congress
Predicting Risk of Cytomegalovirus with Viral-Antigen-Specific CD154+ T-cells after Liver or Intestine Transplantation
Childrens Hospital of Pittsburgh of UPMC, Pittsburgh, PA
*Purpose: Cytomegalovirus (CMV)-specific T-cells express IFNγ, measure cell-mediated immunity to CMV and can guide the timing and duration of antiviral therapy. CMV-specific T-cells also co-express…2019 American Transplant Congress
Ganciclovir Based Prophylaxis against Cytomegalovirus Viremia in Pediatric Renal Transplant Patients: A Systematic Review and Meta-Analysis
*Purpose: Cytomegalovirus (CMV) disease continues to stand as a significant threat to the longevity of renal transplants in children. More pediatric recipients are CMV negative…2018 American Transplant Congress
Th17 and NK Responses Are Differentially Induced in Renal Allografts According to Recipient Murine Cytomegalovirus Dose and Strain
Purpose: To study the impact of cytomegalovirus (CMV) recipient positive (R+) serostatus upon renal allograft injury, murine CMV (MCMV) D+/R+ kidney transplants using recipients infected…2018 American Transplant Congress
Recovery of Wild-Type Genotype after Documented Ganciclovir-Resistance in Transplant Recipients with Recurrent CMV Viremia
Purpose: Ganciclovir-resistant cytomegalovirus (GR-CMV) is serious complication after transplantation. Recurrence after primary GR-CMV infection is common, with literature defined rates of approximately 20-30%. It is…2018 American Transplant Congress
Evaluation of the Use of Oral Valganciclovir for the Treatment of Cytomegalovirus Infections in Pediatric Intestinal Transplant Recipients: A Single Center Review
Purpose: To evaluate the safety and efficacy of oral valganciclovir in treating cytomegalovirus (CMV) infections in pediatric intestinal transplant recipients (pITR).Methods: This retrospective review included…2018 American Transplant Congress
Alveolar Macrophages Derived from MCMV Latently Infected Donors Drives the Viral Reactivation and Dissemination Following the Orthotopic Left Lung Transplantation in Mice
Background: The incidence of cytomegalovirus (CMV) disease is higher in lung transplants, than in other SOT recipients, especially in high-risk D+/R- recipients. Using a murine…2018 American Transplant Congress
Burden of Primary CMV Infections Remains High Despite Six Months Valganciclovir Prophylaxis in High-Risk Kidney Transplant Recipients
A. Prophylaxis has mostly replaced preemptive therapy in CMV seronegative recipients of kidneys from seropositive donors (D+/R-). Primary infections occur commonly even after six months…2018 American Transplant Congress
CMV-Specific CD8+ T-Cell Immune Competence Score as Predictor of Outcome for CMV Infection after Transplantation
Introduction: Control of cytomegalovirus (CMV) infection after solid organ transplantation (SOT) requires a functional immune system. We assessed the utility of a flow cytometric assay…2018 American Transplant Congress
Significant Anti-CMV/BKV Effect of a Modern Everolimus-Based Regimen Comparted to a Standard Tacrolimus-MPA Regimen in De Novo Kidney Transplant Recipients: ATHENA 12 Months Data on Infections
1Athena Study Group, Germany; 2Athena Study Group, France; 3Novartis, Pharma, Germany.
The ATHENA trial was designed to compare everolimus [EVR] in combination with tacrolimus [TAC] or cyclosporine A [CyA] vs. a standard regimen of mycophenolic acid…
- « Previous Page
- 1
- …
- 15
- 16
- 17
- 18
- 19
- …
- 33
- Next Page »